IDSA Home

What's New

House Appropriations Bill Misses the Mark on ID Programs

The House FY 2025 Labor, Health and Human Services and State and Foreign Operations appropriations bills largely flat fund antimicrobial resistance programs at FY 2024 levels even as AMR grows as a serious public health threat.

Update Alert: 2024 IDSA AMR Guidance

The 2024 IDSA AMR Guidance is now live and updates most questions, noting fosfomycin's exclusion for pyelonephritis and cUTI, cautious use of amoxicillin-clavulanic acid for ESBL cystitis, piperacillin-tazobactam's inefficacy for ESBL-E, ceftolozane-tazobactam's new role, updated dosing for ceftazidime-avibactam with aztreonam, and new treatments for resistant bacteria.

IDSA Advocacy Delivers Significant Victory for ID in Proposed Medicare Fee Schedule

The Centers for Medicare and Medicaid Services released its calendar year 2025 Medicare Physician Fee Schedule Proposed Rule July 10, including a new “add-on” code for infectious diseases developed and advocated for by IDSA.